Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3838195 | 0.96 | KMT2A (0.46) | KMT2AALDH1A1THRBATML3MBTL1 | |
| SCHEMBL18589689 | 0.83 | KMT2A (0.41) | KMT2AALDH1A1THRBATML3MBTL1 | |
| SCHEMBL9484355 | 0.81 | CHRM1 (0.51) | KMT2AALDH1A1THRBATML3MBTL1 | |
| SCHEMBL29822414 | 0.78 | CHRM1 (0.49) | ALDH1A1THRBATML3MBTL1GAA | |
| SCHEMBL9596068 | 0.78 | PPM1B (0.46) | KMT2AALDH1A1THRBATML3MBTL1 | |
| SCHEMBL10063523 | 0.77 | CHRM1 (0.51) | ALDH1A1THRBATML3MBTL1GAA | |
| SCHEMBL17354962 | 0.77 | CHRM1 (0.51) | ALDH1A1THRBATML3MBTL1GAA | |
| SCHEMBL304292 | 0.77 | CHRM1 (0.55) | KMT2AALDH1A1THRBATML3MBTL1 | |
| SCHEMBL13321596 | 0.77 | CHRM1 (0.55) | KMT2AALDH1A1THRBATML3MBTL1 | |
| SCHEMBL18618479 | 0.75 | CHRM1 (0.38) | KMT2AALDH1A1THRBATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1253152-B1 | METHOD OF CONVERTING FUNCTIONAL GROUP THROUGH HALOGEN-METAL EXCHANGE REACTION | BANYU PHARMA CO LTD (JP) | 2009-11-04 | — | — | EP | disclosed |
| US-7439535-B2 | Process for exchanging functional groups by halogen-metal exchange reaction | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-10-21 | — | — | US | disclosed |
| US-6946559-B2 | Replacing a halogen atom with an electrophilic group (e.g., a formyl group) using either a mixture of an organomagnesium halide and an alkyllithium or a reaction product of the two, such as trialkylmagnesium lithium | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-09-20 | — | — | US | disclosed |
| US-20050156336-A1 | Process for exchanging functional groups by halogen-metal exchange reaction | MSD K.K. (JP) | 2005-07-21 | — | — | US | disclosed |
| US-20050104233-A1 | Method of substituent introduction through halogen-metal exchange reaction | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-05-19 | — | — | US | disclosed |
| EP-1510510-A1 | METHOD OF SUBSTITUENT INTRODUCTION THROUGH HALOGEN-METAL EXCHANGE REACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20030130511-A1 | Method of converting functional group through halogen-metal exchange reaction | MSD K.K. (JP) | 2003-07-10 | — | — | US | disclosed |
| EP-1253152-A1 | METHOD OF CONVERTING FUNCTIONAL GROUP THROUGH HALOGEN-METAL EXCHANGE REACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050156336-A1 | Process for exchanging functional groups by halogen-metal exchange reaction | SLC39A11, MLX, SLC39A14 | KMT2A 2116/4885ALDH1A1 4684/4885THRB 909/4885 |
| US-20050104233-A1 | Method of substituent introduction through halogen-metal exchange reaction | SLC39A11, SLC30A6, SLC39A3 | KMT2A 129/4885ALDH1A1 1890/4885THRB 3981/4885 |
| US-20030130511-A1 | Method of converting functional group through halogen-metal exchange reaction | MLX, HAX1, ZFX | KMT2A 1634/4885ALDH1A1 4406/4885THRB 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.